Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis.
Polychemotherapy or radiation frequently causes oral mucositis. Until now, only supportive options are available. Palifermin, a recombinant form of the human keratinocyte growth factor can avoid mucositis in patients treated with myeloablative polychemotherapy for allogeneic stem cell transplantation. Here, we present a patient treated with dose-intense conventional polychemotherapy suffering from severe mucositis leading to additional hospitalization. By using palifermin, the mucositis as well as further admissions were totally prevented. Furthermore, application in subsequent chemotherapy cycles demonstrated a safe and efficacious use. Hence, treatment with palifermin can prevent severe mucositis in a patient treated with dose-intense conventional polychemotherapy.
Hueber
Axel J
AJ
Department of Internal Medicine III University of Erlangen - Nuremberg, Germany. axel.hueber@med3.imed.uni-erlangen.de
Leipe
Jan
J
Roesler
Wolf
W
Kalden
Joachim R
JR
Kallert
Stefan
S
Rech
Juergen
J
D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D011994:Recombinant Proteins; D051523:Fibroblast Growth Factor 7